Tumor‐associated antigens: Tn antigen, sTn antigen, and T antigen
The DOI matches its Crossref record; 88 of the 88 references it cites were found in a registry or an index.
Abstract
Glycosylation is one of the major posttranslational modifications of proteins. N‐glycosylation (Asn‐linked) and O‐glycosylation (Ser/Thr‐linked) are the two main forms. Abnormal O‐glycosylation is frequently observed on the surface of tumor cells, and is associated with an adverse outcome and poor prognosis in patients with cancer. O‐glycans (Tn, sTn, and T antigen) can be synthesized in the Golgi apparatus with the aid of several glycosyltransferases (such as T‐synthase and ST6GalNAc‐I) in a suitable environment. The unique molecular chaperone of T‐synthase is Cosmc, which helps T‐synthase to fold correctly in the endoplasmic reticulum. Dysregulation of these glycosyltransferases, molecular chaperones, or the environment is involved in the dysregulation of O‐glycans. Tn, sTn, and T antigen neo‐ or over‐expression occurs in many types of cancer including gastric, colon, breast, lung, esophageal, prostate, and endometrial cancer. This review discusses the major synthetic pathway of O‐glycans and the mechanism by which Tn, sTn, and T antigens promote tumor metastasis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Principles that Govern the Folding of Protein Chains
Anfinsen, C. B. (1973) · Science · doi:10.1126/science.181.4096.223 · Cited by 7,096 · cited 1×
“Although the linear amino acid sequence of a protein determines its most thermodynamically stable, native conformation (26), protein folding in vivo normally requires the assistance of a cellular molecular chaperone system (27).”
BackgroundMolecular chaperones in cellular protein folding
Hartl, F. U. (1996) · Nature · doi:10.1038/381571a0 · Cited by 3,568 · cited 1×
“Although the linear amino acid sequence of a protein determines its most thermodynamically stable, native conformation (26), protein folding in vivo normally requires the assistance of a cellular molecular chaperone system (27).”
BackgroundT and Tn, General Carcinoma Autoantigens
Springer, G. F. (1984) · Science · doi:10.1126/science.6729450 · Cited by 1,009
Bennett, E. P., Mandel, U., Clausen, H., Gerken, T. A., Fritz, T. A., & Tabak, L. A. (2012) · Glycobiology · doi:10.1093/glycob/cwr182 · Cited by 876 · cited 3×
“The synthetic process takes place in the Golgi apparatus, where Ser/Thr residues are exposed on the folded protein (2).”
BackgroundMucin glycan foraging in the human gut microbiome
Tailford, L. E., Crost, E. H., Kavanaugh, D., & Juge, N. (2015) · Frontiers in Genetics · doi:10.3389/fgene.2015.00081 · Cited by 839 · cited 1×
“These extended structures include sulfo-LeX, SLeX, or Sda on core 3 or core 4 O-glycans, all of which have been found on mucins, such as MUC2 secreted from intestinal epithelial cells (IECs) (6, 7, 25).”
BackgroundMucins: A biologically relevant glycan barrier in mucosal protection
Corfield, A. P. (2015) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2014.05.003 · Cited by 568 · cited 3×
“The process of O-glycosylation relies on several glycosyltransferases: (1) ppGalNAcTs, which transfers a GalNAc unit from the donor UDP-GalNAc to a Ser/Thr residue of a protein; (2) core 1 β1,3-galactosyltransferase (core 1 β3GalT or T-synthase), which synthesizes core 1 structure or T antigen; (3) core 3 β1,3-N-acety…”
BackgroundInfluentialJu, T., & Cummings, R. D. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.262438199 · Cited by 487
Randomized Phase IIB Trial of BLP25 Liposome Vaccine in Stage IIIB and IV Non–Small-Cell Lung Cancer
Butts, C., Murray, N., Maksymiuk, A., Goss, G., Marshall, E., Soulières, D., Cormier, Y., Ellis, P., Price, A., Sawhney, R., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.13.011 · Cited by 428 · cited 1×
“The second type is active immunization, for instance, mannan-coupled MUC-1 (a carrier protein of T antigen and Tn antigen), which has already been proven effective in phase III trials (89, 90).”
BackgroundImmunoreactive T and Tn epitopes in cancer diagnosis, prognosis, and immunotherapy
Springer, G. F. (1997) · Journal of Molecular Medicine · doi:10.1007/s001090050144 · Cited by 426 · cited 1×
“Springer attempted to induce a T antigen-specific therapeutic response in humans and successfully immunized breast cancer patients with a T antigen-positive vaccine containing asialoglycophorin (derived from red blood cell membranes), which resulted in a significant improvement of survival (39).”
BackgroundAltered Tumor-Cell Glycosylation Promotes Metastasis
Häuselmann, I., & Borsig, L. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00028 · Cited by 382 · cited 1×
“of lectin molecules such as selectins, siglecs, and galectins, and are thus involved in cancer progression (62).”
BackgroundThe Tn Antigen—Structural Simplicity and Biological Complexity
Ju, T., Otto, V. I., & Cummings, R. D. (2011) · Angewandte Chemie International Edition · doi:10.1002/anie.201002313 · Cited by 363 · cited 2×
“However, in cells lacking functional Cosmc, the newly synthesized T-synthase may link to other molecular chaperones such as Big (binding protein: the major chaperone in the endoplasmic reticulum, also called 78-kDa glucose-regulated protein) and form misfolded T-synthase (15).”
BackgroundMammosphere culture of metastatic breast cancer cells enriches for tumorigenic breast cancer cells
Grimshaw, M. J., Cooper, L., Papazisis, K., Coleman, J. A., Bohnenkamp, H. R., Chiapero-Stanke, L., Taylor-Papadimitriou, J., & Burchell, J. M. (2008) · Breast Cancer Research · doi:10.1186/bcr2106 · Cited by 339 · cited 1×
“This approach results in a non-specific activation of the immune system (98).”
BackgroundYu, L.-G., Andrews, N., Zhao, Q., McKean, D., Williams, J. F., Connor, L. J., Gerasimenko, O. V., Hilkens, J., Hirabayashi, J., Kasai, K., et al. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m606862200 · Cited by 303 · cited 2×
“Numerous studies have reported that the interaction of Gal-3 with MUC-1 via T antigen was a central principle of metastatic cell adhesion in cancer progression (72).”
BackgroundRaz, A., & Lotan, R. (1987) · Cancer and Metastasis Review · doi:10.1007/bf00144274 · Cited by 299
Human Tumor Antigens Tn and Sialyl Tn Arise from Mutations in Cosmc
Ju, T., Lanneau, G. S., Gautam, T., Wang, Y., Xia, B., Stowell, S. R., Willard, M. T., Wang, W., Xia, J. Y., Zuna, R. E., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-2345 · Cited by 292 · cited 2×
“Numerous studies have reported that the expression of Tn and sTn antigens in human tumor cells is related to dysfunctional Cosmc (8, 33).”
BackgroundSelf-citationMiles, D., Roché, H., Martin, M., Perren, T. J., Cameron, D. A., Glaspy, J., Dodwell, D., Parker, J., Mayordomo, J., Tres, A., et al. (2011) · The Oncologist · doi:10.1634/theoncologist.2010-0307 · Cited by 262
Marcos, N. T., Pinho, S., Grandela, C., Cruz, A., Samyn-Petit, B., Harduin-Lepers, A., Almeida, R., Silva, F., Morais, V., Costa, J., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1921 · Cited by 258 · cited 1×
“This phenomenon is reported to be associated with ST6GalNAc-I, which also increases in expression and activity in tumor cells (54, 55).”
BackgroundAvigan, D., Vasir, B., Gong, J., Borges, V., Wu, Z., Uhl, L., Atkins, M., Mier, J., McDermott, D., Smith, T., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0347 · Cited by 246 · cited 1×
“The third type of immunization is the use of dendritic cells pulsed with tumor peptides (94) or cell lysates (95), or fusion of dendritic cells with tumor cells and to generate dendritic cells that present tumor antigens (96, 97).”
BackgroundGlinsky, V. V., Glinsky, G. V., Rittenhouse‐Olson, K., Huflejt, M. E., Glinskii, O. V., Deutscher, S. L., & Quinn, T. P. (2001) · PubMed · Cited by 239
van Vliet, S. J., van Liempt, E., Saeland, E., Aarnoudse, C. A., Appelmelk, B., Irimura, T., Geijtenbeek, T. B. H., Blixt, O., Alvarez, R., van Die, I., et al. (2005) · International Immunology · doi:10.1093/intimm/dxh246 · Cited by 238
The Role of Sialyl-Tn in Cancer
Munkley, J. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17030275 · Cited by 226
Arike, L., & Hansson, G. C. (2016) · Journal of Molecular Biology · doi:10.1016/j.jmb.2016.02.010 · Cited by 224 · cited 4×
“In addition, they are further modified by Gal and GlcNAc and usually terminated by sialic acid, a sulfate group, GalNAc or Fuc (1), which results in the formation of extended structures, such as sialyl-Tn antigen (CD175s, sTn), sialyl core 1 (sialyl T antigen, sT antigen, sT), sialyl Lewis x (SLeX) on core 2 O-glycans…”
BackgroundInfluentialCosmc is an essential chaperone for correct protein O-glycosylation
Wang, Y., Ju, T., Ding, X., Xia, B., Wang, W., Xia, L., He, M., & Cummings, R. D. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0914004107 · Cited by 212
Self-citationDependence on pH of polarized sorting of secreted proteins
Caplan, M. J., Stow, J. L., Newman, A. P., Madri, J., Anderson, H. C., Farquhar, M. G., Palade, G. E., & Jamieson, J. D. (1987) · Nature · doi:10.1038/329632a0 · Cited by 211 · cited 1×
“This treatment also led to the loss of polarized transport of secreted proteins, highlighting the importance of an acidic pH in the secretory pathway (80).”
BackgroundBlixt, O., Bueti, D., Burford, B., Allen, D., Julien, S., Hollingsworth, M., Gammerman, A., Fentiman, I., Taylor-Papadimitriou, J., & Burchell, J. M. (2011) · Breast Cancer Research · doi:10.1186/bcr2841 · Cited by 211 · cited 1×
“This implies that these antibodies may function to suppress tumor development and/or progression (83).”
BackgroundKhaldoyanidi, S. K., Glinsky, V. V., Sikora, L., Glinskii, A. B., Mossine, V. V., Quinn, T. P., Glinsky, G. V., & Sriramarao, P. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m209590200 · Cited by 211 · cited 1×
“The special adhesion property created by the interaction of Gal-3 and T antigen is a main feature of metastasis formation (71).”
BackgroundThe development of synthetic antitumour vaccines from mucin glycopeptide antigens
Gaidzik, N., Westerlind, U., & Kunz, H. (2013) · Chemical Society Reviews · doi:10.1039/c3cs35470a · Cited by 210 · cited 1×
“Furthermore, the glycopeptides can be coupled to immunostimulants and they can produce relatively strong reactions in mouse models (93).”
BackgroundJulien, S., Adriaenssens, E., Ottenberg, K., Furlan, A., Courtand, G., Vercoutter-Edouart, A.-S., Hanisch, F.-G., Delannoy, P., & Le Bourhis, X. (2006) · Glycobiology · doi:10.1093/glycob/cwj033 · Cited by 204 · cited 2×
“This phenomenon is reported to be associated with ST6GalNAc-I, which also increases in expression and activity in tumor cells (54, 55).”
Background(1975) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/54.2.335 · Cited by 188 · cited 1×
“T antigen was detected as a tumor antigen, or more correctly as an oncofetal antigen in 1975 (65).”
BackgroundHigashi, N., Fujioka, K., Denda-Nagai, K., Hashimoto, S.-I., Nagai, S., Sato, T., Fujita, Y., Morikawa, A., Tsuiji, M., Miyata-Takeuchi, M., et al. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m202104200 · Cited by 176
Apostolopoulos, V., Pietersz, G. A., Tsibanis, A., Tsikkinis, A., Drakaki, H., Loveland, B. E., Piddlesden, S. J., Plebanski, M., Pouniotis, D. S., Alexis, M. N., et al. (2006) · Breast Cancer Research · doi:10.1186/bcr1505 · Cited by 173 · cited 1×
“The second type is active immunization, for instance, mannan-coupled MUC-1 (a carrier protein of T antigen and Tn antigen), which has already been proven effective in phase III trials (89, 90).”
BackgroundMannan-MUC1–Pulsed Dendritic Cell Immunotherapy: A Phase I Trial in Patients with Adenocarcinoma
Loveland, B. E., Zhao, A., White, S., Gan, H., Hamilton, K., Xing, P.-X., Pietersz, G. A., Apostolopoulos, V., Vaughan, H., Karanikas, V., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1574 · Cited by 172 · cited 1×
“The third type of immunization is the use of dendritic cells pulsed with tumor peptides (94) or cell lysates (95), or fusion of dendritic cells with tumor cells and to generate dendritic cells that present tumor antigens (96, 97).”
BackgroundTn and sialyl‐Tn antigens, aberrant O‐glycomics as human disease markers
Ju, T., Wang, Y., Aryal, R. P., Lehoux, S. D., Ding, X., Kudelka, M. R., Cutler, C., Zeng, J., Wang, J., Sun, X., et al. (2013) · PROTEOMICS – Clinical Applications · doi:10.1002/prca.201300024 · Cited by 164 · cited 3×
“In addition, they are further modified by Gal and GlcNAc and usually terminated by sialic acid, a sulfate group, GalNAc or Fuc (1), which results in the formation of extended structures, such as sialyl-Tn antigen (CD175s, sTn), sialyl core 1 (sialyl T antigen, sT antigen, sT), sialyl Lewis x (SLeX) on core 2 O-glycans…”
BackgroundSelf-citationPinho, S., Marcos, N. T., Ferreira, B., Carvalho, A. S., Oliveira, M. J., Santos-Silva, F., Harduin-Lepers, A., & Reis, C. A. (2007) · Cancer Letters · doi:10.1016/j.canlet.2006.08.010 · Cited by 162 · cited 1×
“However, sTn antigen may promote tumor cells to migrate and invade underlying tissue, and eventually reach blood or lymph vessels (63).”
BackgroundThe C-type lectin MGL expressed by dendritic cells detects glycan changes on MUC1 in colon carcinoma
Saeland, E., van Vliet, S. J., Bäckström, M., van den Berg, V. C. M., Geijtenbeek, T. B. H., Meijer, G. A., & van Kooyk, Y. (2006) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-006-0274-z · Cited by 158 · cited 1×
“This binding may lead to immunosuppressive effects and enable the tumor to escape from immunosurveillance (5, 51, 52).”
BackgroundThe Cosmc connection to the Tn antigen in cancer
Ju, T., Aryal, R. P., Kudelka, M. R., Wang, Y., & Cummings, R. D. (2014) · Cancer Biomarkers · doi:10.3233/cbm-130375 · Cited by 153 · cited 2×
“Numerous studies have reported that the expression of Tn and sTn antigens in human tumor cells is related to dysfunctional Cosmc (8, 33).”
BackgroundSelf-citationNapoletano, C., Rughetti, A., Agervig Tarp, M. P., Coleman, J., Bennett, E. P., Picco, G., Sale, P., Denda-Nagai, K., Irimura, T., Mandel, U., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-1035 · Cited by 152 · cited 1×
“This binding may lead to immunosuppressive effects and enable the tumor to escape from immunosurveillance (5, 51, 52).”
BackgroundGlycan variation and evolution in the eukaryotes
Corfield, A. P., & Berry, M. (2015) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2015.04.004 · Cited by 149 · cited 1×
“β3GlcNAcT), which synthesizes core 3 structure; (4) sialyltransferase ST6GalNAc-I, which facilitates the synthesis of sialyl-Tn antigen (sTn antigen, sTn) (8, 9).”
BackgroundThorens, B., & Vassalli, P. (1986) · Nature · doi:10.1038/321618a0 · Cited by 147 · cited 1×
“Interestingly, incomplete glycosylation as a result of an experimental increase in the pH of Golgi bodies in plasma cells was demonstrated as early as 1986 (79).”
BackgroundGlinsky, V. V., Huflejt, M. E., Glinsky, G. V., Deutscher, S. L., & Quinn, T. P. (2000) · PubMed · Cited by 141
Lotan, R., Belloni, P., Tressler, R., Lotan, D., Xu, X.-C., & Nicolson, G. L. (1994) · Glycoconjugate Journal · doi:10.1007/bf00731282 · Cited by 139 · cited 1×
“Regulating O-glycosylation (through related glycosyltransferases, molecular chaperones, and antibodies) can positively influence tumor metastasis (31, 32, 68).”
BackgroundCOSMC knockdown mediated aberrant O-glycosylation promotes oncogenic properties in pancreatic cancer
Hofmann, B. T., Schlüter, L., Lange, P. F., Mercanoglu, B., Ewald, F., Fölster, A., Picksak, A.-S., Harder, S., Gammal, A. T. E., Grupp, K., et al. (2015) · Molecular Cancer · doi:10.1186/s12943-015-0386-1 · Cited by 136 · cited 2×
“Cosmc knockdown induces the over-expression of Tn antigen and sTn antigen, which is one of the oncogenic properties in pancreatic cancer (31).”
BackgroundJu, T., Aryal, R. P., Stowell, C. J., & Cummings, R. D. (2008) · The Journal of Cell Biology · doi:10.1083/jcb.200711151 · Cited by 134
Expression of a Specific Glycosyltransferase Enzyme Regulates T Cell Death Mediated by Galectin-1
Galvan, M., Tsuboi, S., Fukuda, M., & Baum, L. G. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m001117200 · Cited by 128 · cited 1×
“Then, core 2 β-1,6-N-acetylglucosaminyltransferase (core 2 GnT) can transfer a GalNAc unit from the donor UDP-GalNAc to T antigen to form core 2 structure (24).”
BackgroundOgata, S., Maimonis, P. J., & Itzkowitz, S. H. (1992) · PubMed · Cited by 120
Beatson, R., Maurstad, G., Picco, G., Arulappu, A., Coleman, J., Wandell, H. H., Clausen, H., Mandel, U., Taylor‐Papadimitriou, J., Sletmoen, M., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0125994 · Cited by 115 · cited 1×
“For instance, sTn antigen promotes individual cells to break away from the primary tumor mass by disrupting the interaction of galectins with terminal galactose residues (30).”
BackgroundSaeland, E., Belo, A. I., Mongera, S., van Die, I., Meijer, G. A., & van Kooyk, Y. (2011) · International Journal of Cancer · doi:10.1002/ijc.26354 · Cited by 112 · cited 1×
“T antigen is usually further modified or extended by glycosyltransferases and sulfotransferases to form complex O-glycans, which affect cellular interactions as these outer structures interact closely with other cells and the extracellular matrix (23).”
BackgroundRivinoja, A., Kokkonen, N., Kellokumpu, I., & Kellokumpu, S. (2006) · Journal of Cellular Physiology · doi:10.1002/jcp.20653 · Cited by 102 · cited 2×
“Direct evidence suggests that the treatment of (non-malignant) COS-7 cells with pH gradient dissipating drugs (BafA1, chloroquine, or NH4Cl) results in an increase of Golgi pH and the expression of intracellular T antigen (81).”
BackgroundThomsson, K. A., Holmén-Larsson, J. M., Ångström, J., Johansson, M. E., Xia, L., & Hansson, G. C. (2012) · Glycobiology · doi:10.1093/glycob/cws083 · Cited by 101 · cited 1×
“These extended structures include sulfo-LeX, SLeX, or Sda on core 3 or core 4 O-glycans, all of which have been found on mucins, such as MUC2 secreted from intestinal epithelial cells (IECs) (6, 7, 25).”
BackgroundMunkley, J., Oltean, S., Vodák, D., Wilson, B. T., Livermore, K. E., Zhou, Y., Star, E., Floros, V. I., Johannessen, B., Knight, B., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.6024 · Cited by 98 · cited 3×
“In prostate cancer, the sTn antigen inhibits the formation of stable tumor masses, which potentially promotes cancer cell dissemination, but has no effect on cancer metastasis (57).”
BackgroundInfluentialBlood group MN specific substances and precursors in normal and malignant human breast tissues
Springer, G. F., Desai, P. R., & Banatwala, I. (1974) · Die Naturwissenschaften · doi:10.1007/bf00597216 · Cited by 94 · cited 1×
“reported that the Tn antigen was highly expressed in 90% of breast carcinomas, which indicated the relationship between Tn antigen and cancer (37).”
BackgroundSialyl-Tn vaccine induces antibody-mediated tumour protection in a relevant murine model
Julien, S., Picco, G., Sewell, R., Vercoutter‐Edouart, A., Tarp, M. S., Miles, D. W., Clausen, H., Taylor-Papadimitriou, J., & Burchell, J. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6605083 · Cited by 94 · cited 1×
“In addition, a Tn-coupled MUC-1 is able to stimulate T-cell-specific responses (86).”
BackgroundLira‐Navarrete, E., Rivas, M. D. L., Compañón, I., Pallarés, M. C., Kong, Y., Iglesias‐Fernández, J., Bernardes, G. J. L., Peregrina, J. M., Rovira, C., Bernadó, P., et al. (2015) · Nature Communications · doi:10.1038/ncomms7937 · Cited by 91 · cited 2×
“Core 1 and core 2 are expressed in many normal tissues, but core 3, core 4, and core 5 are specialized in epithelial cells of the GI tract (Scheme 1) (9, 15, 16).”
BackgroundWang, Z.-Q., Bachvarova, M., Morin, C., Plante, M., Gregoire, J., Renaud, M., Sebastianelli, A., & Bachvarov, D. R. (2014) · Oncotarget · doi:10.18632/oncotarget.1652 · Cited by 91
Miles, D. W., & Papazisis, K. (2003) · Clinical Breast Cancer · doi:10.3816/cbc.2003.s.002 · Cited by 86
Desai, P. R. (2000) · Transfusion Medicine Reviews · doi:10.1053/tmrv.2000.16229 · Cited by 85
van Kooyk, Y., Ilarregui, J. M., & van Vliet, S. J. (2015) · Immunobiology · doi:10.1016/j.imbio.2014.10.002 · Cited by 78
Ozaki, H., Matsuzaki, H., Ando, H., Kaji, H., Nakanishi, H., Ikehara, Y., & Narimatsu, H. (2012) · Clinical & Experimental Metastasis · doi:10.1007/s10585-011-9445-1 · Cited by 78 · cited 1×
“Similar to Tn antigen, sTn up-regulation is linked to increased tumor growth and metastasis in in vivo models of breast and gastric cancer (55, 56).”
BackgroundThe Endoplasmic Reticulum Chaperone Cosmc Directly Promotes in Vitro Folding of T-synthase
Aryal, R. P., Ju, T., & Cummings, R. D. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.065169 · Cited by 75 · cited 1×
“Newly synthesized T-synthase in the endoplasmic reticulum is not glycosylated and lacks N-glycosylation sequons, so it cannot participate in normal O-glycosylation (20).”
BackgroundEndogenous lectins as mediators of tumor cell adhesion
Lotan, R., & Raz, A. (1988) · Journal of Cellular Biochemistry · doi:10.1002/jcb.240370110 · Cited by 75
Bian, C.-F., Zhang, Y., Sun, H. Z., Li, D., & Wang, D. (2011) · PLoS ONE · doi:10.1371/journal.pone.0025007 · Cited by 74 · cited 1×
“T antigen plays a crucial role in the adhesion of cancer cells to the endothelium through interaction with galectin-3, and thereby promotes metastasis (11, 12).”
BackgroundDavidson, B., Berner, A., Nesland, J. M., Risberg, B. Å., Kristensen, G. B., Trope, C. G., & Bryne, M. (2000) · Human Pathology · doi:10.1053/hupa.2000.9776 · Cited by 71 · cited 1×
“Moreover, in ovarian cancer, sTn antigen-positive cells are more frequently observed at the invasive front of tumors compared with metastatic lesions (58, 59).”
BackgroundHung, J., Huang, J. C., Lin, Y.-C., Huang, M.-J., Lee, P., Lai, H., Liang, J., & Huang, M. (2014) · Oncotarget · doi:10.18632/oncotarget.1815 · Cited by 69
Davidson, B., Gotlieb, W. H., Ben‐Baruch, G., Kopolovic, J., Goldberg, I., Nesland, J. M., Berner, A., Bjåmer, A., & Bryne, M. (2000) · Gynecologic Oncology · doi:10.1006/gyno.1999.5708 · Cited by 63 · cited 1×
“Moreover, in ovarian cancer, sTn antigen-positive cells are more frequently observed at the invasive front of tumors compared with metastatic lesions (58, 59).”
BackgroundBaldus, S. E., Zirbes, T. K., Hanisch, F., Kunze, D., Shafizadeh, S. T., Nolden, S., M�nig, S. P., Schneider, P. M., Karsten, U. R., Thiele, J., et al. (2000) · Cancer · Cited by 61 · cited 1×
“T antigen is expressed in 90% of human cancer types, including precancerous lesions (72, 77, 78).”
BackgroundOsteopontin O-glycosylation contributes to its phosphorylation and cell-adhesion properties
Kariya, Y., Kanno, M., Morita‐Matsumoto, K., Konno, M., Yamaguchi, Y., & Hashimoto, Y. (2014) · Biochemical Journal · doi:10.1042/bj20140060 · Cited by 59
Clinical value of sialyl Tn antigen in patients with gynecologic tumors.
Inoue, M., Ogawa, H., Nakanishi, K., Tanizawa, O., Karino, K., & Endo, J. (1990) · PubMed · Cited by 56
Ulsemer, P., Henderson, G., Toutounian, K., Löffler, A., Schmidt, J., Karsten, U. R., Blaut, M., & Goletz, S. (2013) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-013-1394-x · Cited by 52 · cited 1×
“This supports the argument that the Bacteroides ovatus D-6 strain is an almost perfect candidate for the development of the first adjuvant-free T antigen-specific anti-tumor vaccine (76).”
ResultLiu, S., Shun, C., Hung, K., Juan, H., Hsu, C., Huang, M., & Lai, I. (2016) · Oncotarget · doi:10.18632/oncotarget.7081 · Cited by 51
Tamura, F., Sato, Y., Hirakawa, M., Yoshida, M., Ono, M., Osuga, T., Okagawa, Y., Uemura, N., Arihara, Y., Murase, K., et al. (2014) · Gastric Cancer · doi:10.1007/s10120-014-0454-z · Cited by 49 · cited 2×
“In addition, ST6GalNAc-I also regulates the gene expression of insulin-like growth factor-1 (IGF-1) through STAT5b activation in gastric cancer cells, which may be a potential target for treatment of metastasizing gastric cancer (22).”
BackgroundSynthetic glycopeptides for the development of cancer vaccines.
Liakatos, A., & Kunz, H. (2007) · PubMed · Cited by 45
Clinical Development of the STn-KLH Vaccine (Theratope®)
Ibrahim, N. K., & Murray, J. L. (2003) · Clinical Breast Cancer · doi:10.3816/cbc.2003.s.003 · Cited by 44
van Vliet, S. J., Vuist, I. M., Lenos, K., Tefsen, B., Kalay, H., García-Vallejo, J. J., & van Kooyk, Y. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.471045 · Cited by 37 · cited 1×
“Several studies have reported that Tn antigen is bound by the C-type macrophage galactose binding lectin (MGL) in situ in colorectal tumors (47).”
BackgroundHuang, J. C., Che, M., Lin, N., Hung, J., Huang, Y., Lin, W., Huang, H., Lee, P., Liang, J., & Huang, M. (2013) · Molecular Carcinogenesis · doi:10.1002/mc.22011 · Cited by 32 · cited 1×
“Interestingly, in colorectal cancer cells, research has shown that Cosmc promotes malignant phenotypes of colon cancer cells mainly via activation of the MEK/ERK and PI3K/Akt signaling pathways (102).”
BackgroundNewton‐Northup, J., Dickerson, M. T., Ma, L., Besch-Williford, C. L., & Deutscher, S. L. (2012) · Clinical & Experimental Metastasis · doi:10.1007/s10585-012-9516-y · Cited by 32 · cited 1×
“Furthermore, when using the peptide G3-012, which has a high affinity for Gal-3, inhibition of binding between Gal-3 and T antigen led to a decrease in lung colonization (73).”
MethodZeng, J., Mi, R., Wang, Y., Li, Y., Lin, L., Yao, B., Song, L., van Die, I., Chapman, A. B., Cummings, R. D., et al. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.654244 · Cited by 29 · cited 1×
“In epigenetics, Cosmc and T-synthase are transcriptionally regulated at a basal level by the specificity protein/Krüppel-like transcription factor family of members, which explains their ubiquitous and coordinated expression, and indicates that they are both differentially and epigenetically regulated beyond X chromos…”
BackgroundSelf-citationWhat controls the expression of the core-1 (Thomsen—Friedenreich) glycotope on tumor cells?
Karsten, U. R., & Goletz, S. (2015) · Biochemistry (Moscow) · doi:10.1134/s0006297915070019 · Cited by 28 · cited 3×
“Moreover, the molecular chaperone Cosmc is found hypermethylated in 40% of pancreatic tumors (10).”
BackgroundInfluentialBohnenkamp, H. R., Coleman, J., Burchell, J., Taylor‐Papadimitriou, J., & Noll, T. (2004) · Cellular Immunology · doi:10.1016/j.cellimm.2004.12.007 · Cited by 28 · cited 1×
“The third type of immunization is the use of dendritic cells pulsed with tumor peptides (94) or cell lysates (95), or fusion of dendritic cells with tumor cells and to generate dendritic cells that present tumor antigens (96, 97).”
BackgroundFerguson, K., Yadav, A., Morey, S., Abdullah, J., Hrysenko, G., Eng, J. Y., Sajjad, M., Koury, S. T., & Rittenhouse‐Olson, K. (2014) · Future Oncology · doi:10.2217/fon.13.209 · Cited by 27 · cited 4×
“Further studies have demonstrated that humanized JAA-F11 is helpful for immunotherapy and drug conjugation therapy for breast cancer, as it increases the survival rate of patients (75).”
BackgroundInfluentialThe role of TF- and Tn-antigens in breast cancer metastasis.
Kölbl, A. C., Jeschke, U., Friese, K., et al. (2016) · PubMed · doi:10.14670/hh-11-722 · Cited by 23
Aryal, R. P., Ju, T., & Cummings, R. D. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.555870 · Cited by 22 · cited 1×
“This binding may allow Cosmc to sequester T-synthase to promote its folding and prevent T-synthase from forming dead-end oligomers (34).”
BackgroundXie, L., Tan, C., Fan, J., Fu, P., Tang, Y., Tao, Y., & Qin, W. (2012) · International Urology and Nephrology · doi:10.1007/s11255-012-0313-y · Cited by 21
Aberrant Cosmc genes result in Tn antigen expression in human colorectal carcinoma cell line HT-29.
Yu, X., Du, Z., Sun, X., Shi, C., Zhang, H., & Hu, T. (2015) · PubMed Central · Cited by 20
Lee, J., Chen, C., Chen, Y.-H., Huang, M.-J., Huang, J. C., Hung, J., Chen, M.-T., & Huang, M.-C. (2013) · PLoS ONE · doi:10.1371/journal.pone.0056211 · Cited by 18 · cited 1×
“In addition, Cosmc also contributes to the pathogenesis of hemangioma through vascular endothelial growth factor receptor 2 (VEGFR2, KDR/Flk-1) (103).”
BackgroundHaugstad, K. E., Hadjialirezaei, S., Stokke, B. T., Brewer, C. F., Gerken, T. A., Burchell, J., Picco, G., & Sletmoen, M. (2016) · Glycobiology · doi:10.1093/glycob/cww065 · Cited by 13 · cited 1×
“above suggest that sTn antigen plays a transient role in the progression of cancer (64).”
BackgroundNarimatsu, Y., Kubota, T., Furukawa, S., Shimojima, M., Iwasaki, H., Tozawa, Y., Tachibana, K., & Narimatsu, H. (2011) · FEBS Letters · doi:10.1016/j.febslet.2011.04.010 · Cited by 10 · cited 1×
“evidence that Cosmc is needed for co-translational biosynthesis of T-synthase (28).”
BackgroundTaus, C., Windwarder, M., Altmann, F., Grabherr, R. M., & Staudacher, E. (2014) · Glycoconjugate Journal · doi:10.1007/s10719-014-9565-3 · Cited by 10 · cited 1×
“The first step is the transfer of GalNAc from UDP-GalNAc to Ser/Thr residues of a polypeptide by ppGalNAcT, which results in the formation of Tn antigen (17).”
BackgroundChen, H., Zhou, X., Yu, G., Zhao, Y.-L., Ren, Y., Zhou, Y.-D., Li, Q., & Zhang, X. (2012) · Journal of Clinical Immunology · doi:10.1007/s10875-012-9653-8 · Cited by 10 · cited 3×
“We have reported that knockdown of T-synthase can suppress the function of CD8+ T cells (14).”
BackgroundInfluentialSelf-citation
Cited by
Guerreiro, A., Compañón, I., Lazaris, F. S., Labão‐Almeida, C., Oroz, P., Ghirardello, M., Marques, M. C., Corzana, F., & Bernardes, G. J. L. (2024) · Angewandte Chemie International Edition · doi:10.1002/anie.202411009 · Cited by 28
Metadata
- Authors
- Fu, C., Zhao, H., Wang, Y., Cai, H., Xiao, Y., Zeng, Y., & Chen, H.
- Venue
- HLA
- Publisher
- Wiley
- Published
- 2016-09-28
- Volume
- 88
- Issue
- 6
- Pages
- 275-286
- ISSN
- 2059-2302 (ISSN-L)
- 2059-2310
- OpenAlex
- W2528779404
- Cited by
- 219
- References
- 88
- FWCI
- 4.36
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.